Reply:
Zhao‐Ning Lu, Ze‐Guang Han – 14 October 2019
Changing Etiologies and Prognostic Factors in Pediatric Acute Liver Failure
Manuel Mendizabal, Marcelo Dip, Ezequiel Demirdjian, Leandro Lauferman, Susana Lopez, Julia Minetto, Alejandro Costaguta, Carolina Rumbo, Ivone Malla, María Camila Sanchez, Esteban Halac, Guillermo Cervio, Miriam Cuarterolo, Marcela Galoppo, Oscar Imventarza, Liliana Bisgniano, Daniel D’Agostino, Fernando Rubinstein – 13 October 2019 – After the implementation of universal hepatitis A virus vaccination in Argentina, the outcome of pediatric acute liver failure (PALF) remains unknown.
Everolimus: Longer‐Term CERTITUDE
Omar Y. Mousa, Andrew P. Keaveny – 13 October 2019
Tuberculosis Treatment With a 3‐Drug Rifamycin‐Free Regimen in Liver Transplant Recipients
Timothy Sullivan, Samantha Jacobs, Jennifer Leong, Dallas Dunn, Emily Baneman, Sarah Taimur, Shirish Huprikar, Meenakshi Rana – 13 October 2019
Advanced Practice Providers: Raising Our Defenses Against the Rising Tide of Cirrhosis
Ashley M. Hyde, Michelle Carbonneau, Juan G. Abraldes, Puneeta Tandon – 12 October 2019
Novel Arterial Reconstruction With Donor Femoral Artery in Split‐Liver Transplantation
Flavio Paterno, Lloyd Brown, Dorian Wilson, Nikolaos Pyrsopoulos, James V. Guarrera – 12 October 2019
qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis
Feng Liu, George Boon‐Bee Goh, Dina Tiniakos, Aileen Wee, Wei‐Qiang Leow, Jing‐Min Zhao, Hui‐Ying Rao, Xiao‐Xiao Wang, Qin Wang, Wei‐Keat Wan, Kiat‐Hon Lim, Manuel Romero‐Gomez, Salvatore Petta, Elisabetta Bugianesi, Chee‐Kiat Tan, Stephen A. Harrison, Quentin M. Anstee, Pik‐Eu Jason Chang, Lai Wei – 10 October 2019
Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B
Anna S. Lok, Fabien Zoulim, Geoffrey Dusheiko, Henry L.Y. Chan, Maria Buti, Marc G. Ghany, Anuj Gaggar, Jenny C. Yang, George Wu, John F. Flaherty, G. Mani Subramanian, Stephen Locarnini, Patrick Marcellin – 10 October 2019 – In patients with chronic hepatitis B (CHB), loss of hepatitis B surface antigen (HBsAg) is considered a functional cure. However, HBsAg loss is uncommon with existing therapies, and predictive factors associated with HBsAg seroreversion are unknown.
Liver‐Targeted Angiotensin Converting Enzyme 2 Therapy Inhibits Chronic Biliary Fibrosis in Multiple Drug‐Resistant Gene 2‐Knockout Mice
Indu G. Rajapaksha, Lakmie S. Gunarathne, Khashayar Asadi, Sharon C. Cunningham, Alexandra Sharland, Ian E. Alexander, Peter W. Angus, Chandana B. Herath – 10 October 2019 – There is a large unmet need for effective therapies for cholestatic disorders, including primary sclerosing cholangitis (PSC), a disease that commonly results in liver failure. Angiotensin (Ang) II of the renin Ang system (RAS) is a potent profibrotic peptide, and Ang converting enzyme 2 (ACE2) of the alternate RAS breaks down Ang II to antifibrotic peptide Ang‐(1‐7).
Nontranscriptional Activity of Interferon Regulatory Factor 3 Protects Mice From High‐Fat Diet‐Induced Liver Injury
Carlos Sanz‐Garcia, Megan R. McMullen, Saurabh Chattopadhyay, Sanjoy Roychowdhury, Ganes Sen, Laura E. Nagy – 10 October 2019 – Interferon regulatory factor 3 (IRF3) has both transcriptional and nontranscriptional functions. Transcriptional activity is dependent on serine phosphorylation of IRF3, while transcription‐independent IRF3‐mediated apoptosis requires ubiquitination. IRF3 also binds to inhibitor of nuclear factor kappa B kinase (IKKβ) in the cytosol, restricting nuclear translocation of p65.